Global Giant Cell Arteritis Therapeutic Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Giant Cell Arteritis Therapeutic market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.
This report is a detailed and comprehensive analysis for global Giant Cell Arteritis Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Giant Cell Arteritis Therapeutic market size and forecasts, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Giant Cell Arteritis Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Giant Cell Arteritis Therapeutic market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc and F. Hoffmann-La Roche Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Giant Cell Arteritis Therapeutic market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Giant Cell Arteritis Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Giant Cell Arteritis Therapeutic, with revenue, gross margin and global market share of Giant Cell Arteritis Therapeutic from 2018 to 2023.
Chapter 3, the Giant Cell Arteritis Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Giant Cell Arteritis Therapeutic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Giant Cell Arteritis Therapeutic.
Chapter 13, to describe Giant Cell Arteritis Therapeutic research findings and conclusion.
Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis. It is the most common form of systemic vasculitis, with an incidence of between 15 and 25 cases per 100,000 persons over 50 years of age.
This report is a detailed and comprehensive analysis for global Giant Cell Arteritis Therapeutic market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Giant Cell Arteritis Therapeutic market size and forecasts, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Giant Cell Arteritis Therapeutic market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Giant Cell Arteritis Therapeutic
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Giant Cell Arteritis Therapeutic market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Kiniksa Pharmaceuticals, Ltd., Regeneron, GlaxoSmithKline plc and F. Hoffmann-La Roche Ltd., etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Giant Cell Arteritis Therapeutic market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Prednisone
- Methotrexate
- Tocilizumab
- Aspirin
- Corticosteroids
- Immunosuppressive Agents
- Anticoagulants
- Others
- Sanofi
- Kiniksa Pharmaceuticals, Ltd.
- Regeneron
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- AbbVie, Inc.
- Bristol-Myers Squibb Company
- Abbott
- Johnson & Johnson Services, Inc.
- Johns Hopkins Hospital
- Fortis Healthcare
- American College of Rheumatology
- Duke University Health System
- Lahey Clinic Foundation
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Giant Cell Arteritis Therapeutic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Giant Cell Arteritis Therapeutic, with revenue, gross margin and global market share of Giant Cell Arteritis Therapeutic from 2018 to 2023.
Chapter 3, the Giant Cell Arteritis Therapeutic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Giant Cell Arteritis Therapeutic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Giant Cell Arteritis Therapeutic.
Chapter 13, to describe Giant Cell Arteritis Therapeutic research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Giant Cell Arteritis Therapeutic
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Giant Cell Arteritis Therapeutic by Type
1.3.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type in 2022
1.3.3 Prednisone
1.3.4 Methotrexate
1.3.5 Tocilizumab
1.3.6 Aspirin
1.4 Global Giant Cell Arteritis Therapeutic Market by Application
1.4.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Corticosteroids
1.4.3 Immunosuppressive Agents
1.4.4 Anticoagulants
1.4.5 Others
1.5 Global Giant Cell Arteritis Therapeutic Market Size & Forecast
1.6 Global Giant Cell Arteritis Therapeutic Market Size and Forecast by Region
1.6.1 Global Giant Cell Arteritis Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Giant Cell Arteritis Therapeutic Market Size by Region, (2018-2029)
1.6.3 North America Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.4 Europe Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.6 South America Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Giant Cell Arteritis Therapeutic Product and Solutions
2.1.4 Sanofi Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Kiniksa Pharmaceuticals, Ltd.
2.2.1 Kiniksa Pharmaceuticals, Ltd. Details
2.2.2 Kiniksa Pharmaceuticals, Ltd. Major Business
2.2.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
2.2.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments and Future Plans
2.3 Regeneron
2.3.1 Regeneron Details
2.3.2 Regeneron Major Business
2.3.3 Regeneron Giant Cell Arteritis Therapeutic Product and Solutions
2.3.4 Regeneron Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Regeneron Recent Developments and Future Plans
2.4 GlaxoSmithKline plc
2.4.1 GlaxoSmithKline plc Details
2.4.2 GlaxoSmithKline plc Major Business
2.4.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product and Solutions
2.4.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 F. Hoffmann-La Roche Ltd. Details
2.5.2 F. Hoffmann-La Roche Ltd. Major Business
2.5.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
2.5.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Giant Cell Arteritis Therapeutic Product and Solutions
2.6.4 Novartis AG Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis AG Recent Developments and Future Plans
2.7 AbbVie, Inc.
2.7.1 AbbVie, Inc. Details
2.7.2 AbbVie, Inc. Major Business
2.7.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
2.7.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 AbbVie, Inc. Recent Developments and Future Plans
2.8 Bristol-Myers Squibb Company
2.8.1 Bristol-Myers Squibb Company Details
2.8.2 Bristol-Myers Squibb Company Major Business
2.8.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product and Solutions
2.8.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.9 Abbott
2.9.1 Abbott Details
2.9.2 Abbott Major Business
2.9.3 Abbott Giant Cell Arteritis Therapeutic Product and Solutions
2.9.4 Abbott Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Abbott Recent Developments and Future Plans
2.10 Johnson & Johnson Services, Inc.
2.10.1 Johnson & Johnson Services, Inc. Details
2.10.2 Johnson & Johnson Services, Inc. Major Business
2.10.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
2.10.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Johnson & Johnson Services, Inc. Recent Developments and Future Plans
2.11 Johns Hopkins Hospital
2.11.1 Johns Hopkins Hospital Details
2.11.2 Johns Hopkins Hospital Major Business
2.11.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product and Solutions
2.11.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Johns Hopkins Hospital Recent Developments and Future Plans
2.12 Fortis Healthcare
2.12.1 Fortis Healthcare Details
2.12.2 Fortis Healthcare Major Business
2.12.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Product and Solutions
2.12.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Fortis Healthcare Recent Developments and Future Plans
2.13 American College of Rheumatology
2.13.1 American College of Rheumatology Details
2.13.2 American College of Rheumatology Major Business
2.13.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Product and Solutions
2.13.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 American College of Rheumatology Recent Developments and Future Plans
2.14 Duke University Health System
2.14.1 Duke University Health System Details
2.14.2 Duke University Health System Major Business
2.14.3 Duke University Health System Giant Cell Arteritis Therapeutic Product and Solutions
2.14.4 Duke University Health System Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Duke University Health System Recent Developments and Future Plans
2.15 Lahey Clinic Foundation
2.15.1 Lahey Clinic Foundation Details
2.15.2 Lahey Clinic Foundation Major Business
2.15.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product and Solutions
2.15.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Lahey Clinic Foundation Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Giant Cell Arteritis Therapeutic Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Giant Cell Arteritis Therapeutic by Company Revenue
3.2.2 Top 3 Giant Cell Arteritis Therapeutic Players Market Share in 2022
3.2.3 Top 6 Giant Cell Arteritis Therapeutic Players Market Share in 2022
3.3 Giant Cell Arteritis Therapeutic Market: Overall Company Footprint Analysis
3.3.1 Giant Cell Arteritis Therapeutic Market: Region Footprint
3.3.2 Giant Cell Arteritis Therapeutic Market: Company Product Type Footprint
3.3.3 Giant Cell Arteritis Therapeutic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Giant Cell Arteritis Therapeutic Consumption Value and Market Share by Type (2018-2023)
4.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2023)
5.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
6.2 North America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
6.3 North America Giant Cell Arteritis Therapeutic Market Size by Country
6.3.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
6.3.2 United States Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
6.3.3 Canada Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
6.3.4 Mexico Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
7.2 Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
7.3 Europe Giant Cell Arteritis Therapeutic Market Size by Country
7.3.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
7.3.2 Germany Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.3 France Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.5 Russia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.6 Italy Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size by Region
8.3.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2018-2029)
8.3.2 China Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.3 Japan Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.4 South Korea Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.5 India Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.7 Australia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
9.2 South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
9.3 South America Giant Cell Arteritis Therapeutic Market Size by Country
9.3.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
9.3.2 Brazil Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
9.3.3 Argentina Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Country
10.3.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
10.3.2 Turkey Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10.3.4 UAE Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Giant Cell Arteritis Therapeutic Market Drivers
11.2 Giant Cell Arteritis Therapeutic Market Restraints
11.3 Giant Cell Arteritis Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Giant Cell Arteritis Therapeutic Industry Chain
12.2 Giant Cell Arteritis Therapeutic Upstream Analysis
12.3 Giant Cell Arteritis Therapeutic Midstream Analysis
12.4 Giant Cell Arteritis Therapeutic Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Giant Cell Arteritis Therapeutic
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Giant Cell Arteritis Therapeutic by Type
1.3.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type in 2022
1.3.3 Prednisone
1.3.4 Methotrexate
1.3.5 Tocilizumab
1.3.6 Aspirin
1.4 Global Giant Cell Arteritis Therapeutic Market by Application
1.4.1 Overview: Global Giant Cell Arteritis Therapeutic Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Corticosteroids
1.4.3 Immunosuppressive Agents
1.4.4 Anticoagulants
1.4.5 Others
1.5 Global Giant Cell Arteritis Therapeutic Market Size & Forecast
1.6 Global Giant Cell Arteritis Therapeutic Market Size and Forecast by Region
1.6.1 Global Giant Cell Arteritis Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Giant Cell Arteritis Therapeutic Market Size by Region, (2018-2029)
1.6.3 North America Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.4 Europe Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.6 South America Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Giant Cell Arteritis Therapeutic Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Giant Cell Arteritis Therapeutic Product and Solutions
2.1.4 Sanofi Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Kiniksa Pharmaceuticals, Ltd.
2.2.1 Kiniksa Pharmaceuticals, Ltd. Details
2.2.2 Kiniksa Pharmaceuticals, Ltd. Major Business
2.2.3 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
2.2.4 Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Kiniksa Pharmaceuticals, Ltd. Recent Developments and Future Plans
2.3 Regeneron
2.3.1 Regeneron Details
2.3.2 Regeneron Major Business
2.3.3 Regeneron Giant Cell Arteritis Therapeutic Product and Solutions
2.3.4 Regeneron Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Regeneron Recent Developments and Future Plans
2.4 GlaxoSmithKline plc
2.4.1 GlaxoSmithKline plc Details
2.4.2 GlaxoSmithKline plc Major Business
2.4.3 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product and Solutions
2.4.4 GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche Ltd.
2.5.1 F. Hoffmann-La Roche Ltd. Details
2.5.2 F. Hoffmann-La Roche Ltd. Major Business
2.5.3 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
2.5.4 F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.6 Novartis AG
2.6.1 Novartis AG Details
2.6.2 Novartis AG Major Business
2.6.3 Novartis AG Giant Cell Arteritis Therapeutic Product and Solutions
2.6.4 Novartis AG Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Novartis AG Recent Developments and Future Plans
2.7 AbbVie, Inc.
2.7.1 AbbVie, Inc. Details
2.7.2 AbbVie, Inc. Major Business
2.7.3 AbbVie, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
2.7.4 AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 AbbVie, Inc. Recent Developments and Future Plans
2.8 Bristol-Myers Squibb Company
2.8.1 Bristol-Myers Squibb Company Details
2.8.2 Bristol-Myers Squibb Company Major Business
2.8.3 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product and Solutions
2.8.4 Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.9 Abbott
2.9.1 Abbott Details
2.9.2 Abbott Major Business
2.9.3 Abbott Giant Cell Arteritis Therapeutic Product and Solutions
2.9.4 Abbott Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Abbott Recent Developments and Future Plans
2.10 Johnson & Johnson Services, Inc.
2.10.1 Johnson & Johnson Services, Inc. Details
2.10.2 Johnson & Johnson Services, Inc. Major Business
2.10.3 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
2.10.4 Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Johnson & Johnson Services, Inc. Recent Developments and Future Plans
2.11 Johns Hopkins Hospital
2.11.1 Johns Hopkins Hospital Details
2.11.2 Johns Hopkins Hospital Major Business
2.11.3 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product and Solutions
2.11.4 Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Johns Hopkins Hospital Recent Developments and Future Plans
2.12 Fortis Healthcare
2.12.1 Fortis Healthcare Details
2.12.2 Fortis Healthcare Major Business
2.12.3 Fortis Healthcare Giant Cell Arteritis Therapeutic Product and Solutions
2.12.4 Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Fortis Healthcare Recent Developments and Future Plans
2.13 American College of Rheumatology
2.13.1 American College of Rheumatology Details
2.13.2 American College of Rheumatology Major Business
2.13.3 American College of Rheumatology Giant Cell Arteritis Therapeutic Product and Solutions
2.13.4 American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 American College of Rheumatology Recent Developments and Future Plans
2.14 Duke University Health System
2.14.1 Duke University Health System Details
2.14.2 Duke University Health System Major Business
2.14.3 Duke University Health System Giant Cell Arteritis Therapeutic Product and Solutions
2.14.4 Duke University Health System Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Duke University Health System Recent Developments and Future Plans
2.15 Lahey Clinic Foundation
2.15.1 Lahey Clinic Foundation Details
2.15.2 Lahey Clinic Foundation Major Business
2.15.3 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product and Solutions
2.15.4 Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Lahey Clinic Foundation Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Giant Cell Arteritis Therapeutic Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Giant Cell Arteritis Therapeutic by Company Revenue
3.2.2 Top 3 Giant Cell Arteritis Therapeutic Players Market Share in 2022
3.2.3 Top 6 Giant Cell Arteritis Therapeutic Players Market Share in 2022
3.3 Giant Cell Arteritis Therapeutic Market: Overall Company Footprint Analysis
3.3.1 Giant Cell Arteritis Therapeutic Market: Region Footprint
3.3.2 Giant Cell Arteritis Therapeutic Market: Company Product Type Footprint
3.3.3 Giant Cell Arteritis Therapeutic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Giant Cell Arteritis Therapeutic Consumption Value and Market Share by Type (2018-2023)
4.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2023)
5.2 Global Giant Cell Arteritis Therapeutic Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
6.2 North America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
6.3 North America Giant Cell Arteritis Therapeutic Market Size by Country
6.3.1 North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
6.3.2 United States Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
6.3.3 Canada Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
6.3.4 Mexico Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
7.2 Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
7.3 Europe Giant Cell Arteritis Therapeutic Market Size by Country
7.3.1 Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
7.3.2 Germany Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.3 France Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.5 Russia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
7.3.6 Italy Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Giant Cell Arteritis Therapeutic Market Size by Region
8.3.1 Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2018-2029)
8.3.2 China Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.3 Japan Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.4 South Korea Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.5 India Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
8.3.7 Australia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
9.2 South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
9.3 South America Giant Cell Arteritis Therapeutic Market Size by Country
9.3.1 South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
9.3.2 Brazil Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
9.3.3 Argentina Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Giant Cell Arteritis Therapeutic Market Size by Country
10.3.1 Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2029)
10.3.2 Turkey Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
10.3.4 UAE Giant Cell Arteritis Therapeutic Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Giant Cell Arteritis Therapeutic Market Drivers
11.2 Giant Cell Arteritis Therapeutic Market Restraints
11.3 Giant Cell Arteritis Therapeutic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Giant Cell Arteritis Therapeutic Industry Chain
12.2 Giant Cell Arteritis Therapeutic Upstream Analysis
12.3 Giant Cell Arteritis Therapeutic Midstream Analysis
12.4 Giant Cell Arteritis Therapeutic Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Giant Cell Arteritis Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Giant Cell Arteritis Therapeutic Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Giant Cell Arteritis Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Giant Cell Arteritis Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sanofi Company Information, Head Office, and Major Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Giant Cell Arteritis Therapeutic Product and Solutions
Table 8. Sanofi Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sanofi Recent Developments and Future Plans
Table 10. Kiniksa Pharmaceuticals, Ltd. Company Information, Head Office, and Major Competitors
Table 11. Kiniksa Pharmaceuticals, Ltd. Major Business
Table 12. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
Table 13. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Kiniksa Pharmaceuticals, Ltd. Recent Developments and Future Plans
Table 15. Regeneron Company Information, Head Office, and Major Competitors
Table 16. Regeneron Major Business
Table 17. Regeneron Giant Cell Arteritis Therapeutic Product and Solutions
Table 18. Regeneron Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Regeneron Recent Developments and Future Plans
Table 20. GlaxoSmithKline plc Company Information, Head Office, and Major Competitors
Table 21. GlaxoSmithKline plc Major Business
Table 22. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product and Solutions
Table 23. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. GlaxoSmithKline plc Recent Developments and Future Plans
Table 25. F. Hoffmann-La Roche Ltd. Company Information, Head Office, and Major Competitors
Table 26. F. Hoffmann-La Roche Ltd. Major Business
Table 27. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
Table 28. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Table 30. Novartis AG Company Information, Head Office, and Major Competitors
Table 31. Novartis AG Major Business
Table 32. Novartis AG Giant Cell Arteritis Therapeutic Product and Solutions
Table 33. Novartis AG Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Novartis AG Recent Developments and Future Plans
Table 35. AbbVie, Inc. Company Information, Head Office, and Major Competitors
Table 36. AbbVie, Inc. Major Business
Table 37. AbbVie, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
Table 38. AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. AbbVie, Inc. Recent Developments and Future Plans
Table 40. Bristol-Myers Squibb Company Company Information, Head Office, and Major Competitors
Table 41. Bristol-Myers Squibb Company Major Business
Table 42. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product and Solutions
Table 43. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Bristol-Myers Squibb Company Recent Developments and Future Plans
Table 45. Abbott Company Information, Head Office, and Major Competitors
Table 46. Abbott Major Business
Table 47. Abbott Giant Cell Arteritis Therapeutic Product and Solutions
Table 48. Abbott Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Abbott Recent Developments and Future Plans
Table 50. Johnson & Johnson Services, Inc. Company Information, Head Office, and Major Competitors
Table 51. Johnson & Johnson Services, Inc. Major Business
Table 52. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
Table 53. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Johnson & Johnson Services, Inc. Recent Developments and Future Plans
Table 55. Johns Hopkins Hospital Company Information, Head Office, and Major Competitors
Table 56. Johns Hopkins Hospital Major Business
Table 57. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product and Solutions
Table 58. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Johns Hopkins Hospital Recent Developments and Future Plans
Table 60. Fortis Healthcare Company Information, Head Office, and Major Competitors
Table 61. Fortis Healthcare Major Business
Table 62. Fortis Healthcare Giant Cell Arteritis Therapeutic Product and Solutions
Table 63. Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Fortis Healthcare Recent Developments and Future Plans
Table 65. American College of Rheumatology Company Information, Head Office, and Major Competitors
Table 66. American College of Rheumatology Major Business
Table 67. American College of Rheumatology Giant Cell Arteritis Therapeutic Product and Solutions
Table 68. American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. American College of Rheumatology Recent Developments and Future Plans
Table 70. Duke University Health System Company Information, Head Office, and Major Competitors
Table 71. Duke University Health System Major Business
Table 72. Duke University Health System Giant Cell Arteritis Therapeutic Product and Solutions
Table 73. Duke University Health System Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Duke University Health System Recent Developments and Future Plans
Table 75. Lahey Clinic Foundation Company Information, Head Office, and Major Competitors
Table 76. Lahey Clinic Foundation Major Business
Table 77. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product and Solutions
Table 78. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Lahey Clinic Foundation Recent Developments and Future Plans
Table 80. Global Giant Cell Arteritis Therapeutic Revenue (USD Million) by Players (2018-2023)
Table 81. Global Giant Cell Arteritis Therapeutic Revenue Share by Players (2018-2023)
Table 82. Breakdown of Giant Cell Arteritis Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Giant Cell Arteritis Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Giant Cell Arteritis Therapeutic Players
Table 85. Giant Cell Arteritis Therapeutic Market: Company Product Type Footprint
Table 86. Giant Cell Arteritis Therapeutic Market: Company Product Application Footprint
Table 87. Giant Cell Arteritis Therapeutic New Market Entrants and Barriers to Market Entry
Table 88. Giant Cell Arteritis Therapeutic Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Giant Cell Arteritis Therapeutic Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Giant Cell Arteritis Therapeutic Consumption Value Share by Type (2018-2023)
Table 91. Global Giant Cell Arteritis Therapeutic Consumption Value Forecast by Type (2024-2029)
Table 92. Global Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023)
Table 93. Global Giant Cell Arteritis Therapeutic Consumption Value Forecast by Application (2024-2029)
Table 94. North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Giant Cell Arteritis Therapeutic Raw Material
Table 125. Key Suppliers of Giant Cell Arteritis Therapeutic Raw Materials
Table 1. Global Giant Cell Arteritis Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Giant Cell Arteritis Therapeutic Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Giant Cell Arteritis Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Giant Cell Arteritis Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sanofi Company Information, Head Office, and Major Competitors
Table 6. Sanofi Major Business
Table 7. Sanofi Giant Cell Arteritis Therapeutic Product and Solutions
Table 8. Sanofi Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sanofi Recent Developments and Future Plans
Table 10. Kiniksa Pharmaceuticals, Ltd. Company Information, Head Office, and Major Competitors
Table 11. Kiniksa Pharmaceuticals, Ltd. Major Business
Table 12. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
Table 13. Kiniksa Pharmaceuticals, Ltd. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Kiniksa Pharmaceuticals, Ltd. Recent Developments and Future Plans
Table 15. Regeneron Company Information, Head Office, and Major Competitors
Table 16. Regeneron Major Business
Table 17. Regeneron Giant Cell Arteritis Therapeutic Product and Solutions
Table 18. Regeneron Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Regeneron Recent Developments and Future Plans
Table 20. GlaxoSmithKline plc Company Information, Head Office, and Major Competitors
Table 21. GlaxoSmithKline plc Major Business
Table 22. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Product and Solutions
Table 23. GlaxoSmithKline plc Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. GlaxoSmithKline plc Recent Developments and Future Plans
Table 25. F. Hoffmann-La Roche Ltd. Company Information, Head Office, and Major Competitors
Table 26. F. Hoffmann-La Roche Ltd. Major Business
Table 27. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Product and Solutions
Table 28. F. Hoffmann-La Roche Ltd. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Table 30. Novartis AG Company Information, Head Office, and Major Competitors
Table 31. Novartis AG Major Business
Table 32. Novartis AG Giant Cell Arteritis Therapeutic Product and Solutions
Table 33. Novartis AG Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Novartis AG Recent Developments and Future Plans
Table 35. AbbVie, Inc. Company Information, Head Office, and Major Competitors
Table 36. AbbVie, Inc. Major Business
Table 37. AbbVie, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
Table 38. AbbVie, Inc. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. AbbVie, Inc. Recent Developments and Future Plans
Table 40. Bristol-Myers Squibb Company Company Information, Head Office, and Major Competitors
Table 41. Bristol-Myers Squibb Company Major Business
Table 42. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Product and Solutions
Table 43. Bristol-Myers Squibb Company Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Bristol-Myers Squibb Company Recent Developments and Future Plans
Table 45. Abbott Company Information, Head Office, and Major Competitors
Table 46. Abbott Major Business
Table 47. Abbott Giant Cell Arteritis Therapeutic Product and Solutions
Table 48. Abbott Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Abbott Recent Developments and Future Plans
Table 50. Johnson & Johnson Services, Inc. Company Information, Head Office, and Major Competitors
Table 51. Johnson & Johnson Services, Inc. Major Business
Table 52. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Product and Solutions
Table 53. Johnson & Johnson Services, Inc. Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Johnson & Johnson Services, Inc. Recent Developments and Future Plans
Table 55. Johns Hopkins Hospital Company Information, Head Office, and Major Competitors
Table 56. Johns Hopkins Hospital Major Business
Table 57. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Product and Solutions
Table 58. Johns Hopkins Hospital Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Johns Hopkins Hospital Recent Developments and Future Plans
Table 60. Fortis Healthcare Company Information, Head Office, and Major Competitors
Table 61. Fortis Healthcare Major Business
Table 62. Fortis Healthcare Giant Cell Arteritis Therapeutic Product and Solutions
Table 63. Fortis Healthcare Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Fortis Healthcare Recent Developments and Future Plans
Table 65. American College of Rheumatology Company Information, Head Office, and Major Competitors
Table 66. American College of Rheumatology Major Business
Table 67. American College of Rheumatology Giant Cell Arteritis Therapeutic Product and Solutions
Table 68. American College of Rheumatology Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. American College of Rheumatology Recent Developments and Future Plans
Table 70. Duke University Health System Company Information, Head Office, and Major Competitors
Table 71. Duke University Health System Major Business
Table 72. Duke University Health System Giant Cell Arteritis Therapeutic Product and Solutions
Table 73. Duke University Health System Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Duke University Health System Recent Developments and Future Plans
Table 75. Lahey Clinic Foundation Company Information, Head Office, and Major Competitors
Table 76. Lahey Clinic Foundation Major Business
Table 77. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Product and Solutions
Table 78. Lahey Clinic Foundation Giant Cell Arteritis Therapeutic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Lahey Clinic Foundation Recent Developments and Future Plans
Table 80. Global Giant Cell Arteritis Therapeutic Revenue (USD Million) by Players (2018-2023)
Table 81. Global Giant Cell Arteritis Therapeutic Revenue Share by Players (2018-2023)
Table 82. Breakdown of Giant Cell Arteritis Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 83. Market Position of Players in Giant Cell Arteritis Therapeutic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 84. Head Office of Key Giant Cell Arteritis Therapeutic Players
Table 85. Giant Cell Arteritis Therapeutic Market: Company Product Type Footprint
Table 86. Giant Cell Arteritis Therapeutic Market: Company Product Application Footprint
Table 87. Giant Cell Arteritis Therapeutic New Market Entrants and Barriers to Market Entry
Table 88. Giant Cell Arteritis Therapeutic Mergers, Acquisition, Agreements, and Collaborations
Table 89. Global Giant Cell Arteritis Therapeutic Consumption Value (USD Million) by Type (2018-2023)
Table 90. Global Giant Cell Arteritis Therapeutic Consumption Value Share by Type (2018-2023)
Table 91. Global Giant Cell Arteritis Therapeutic Consumption Value Forecast by Type (2024-2029)
Table 92. Global Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023)
Table 93. Global Giant Cell Arteritis Therapeutic Consumption Value Forecast by Application (2024-2029)
Table 94. North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 95. North America Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 96. North America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 97. North America Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 98. North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 99. North America Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 100. Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 101. Europe Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 102. Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 103. Europe Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 104. Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 105. Europe Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 106. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 107. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 108. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 109. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 110. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2018-2023) & (USD Million)
Table 111. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value by Region (2024-2029) & (USD Million)
Table 112. South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 113. South America Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 114. South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 115. South America Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 116. South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 117. South America Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 118. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2018-2023) & (USD Million)
Table 119. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Type (2024-2029) & (USD Million)
Table 120. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2018-2023) & (USD Million)
Table 121. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Application (2024-2029) & (USD Million)
Table 122. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2018-2023) & (USD Million)
Table 123. Middle East & Africa Giant Cell Arteritis Therapeutic Consumption Value by Country (2024-2029) & (USD Million)
Table 124. Giant Cell Arteritis Therapeutic Raw Material
Table 125. Key Suppliers of Giant Cell Arteritis Therapeutic Raw Materials
LIST OF FIGURES
Figure 1. Giant Cell Arteritis Therapeutic Picture
Figure 2. Global Giant Cell Arteritis Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type in 2022
Figure 4. Prednisone
Figure 5. Methotrexate
Figure 6. Tocilizumab
Figure 7. Aspirin
Figure 8. Global Giant Cell Arteritis Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application in 2022
Figure 10. Corticosteroids Picture
Figure 11. Immunosuppressive Agents Picture
Figure 12. Anticoagulants Picture
Figure 13. Others Picture
Figure 14. Global Giant Cell Arteritis Therapeutic Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Giant Cell Arteritis Therapeutic Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Giant Cell Arteritis Therapeutic Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Region in 2022
Figure 19. North America Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Giant Cell Arteritis Therapeutic Revenue Share by Players in 2022
Figure 25. Giant Cell Arteritis Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Giant Cell Arteritis Therapeutic Market Share in 2022
Figure 27. Global Top 6 Players Giant Cell Arteritis Therapeutic Market Share in 2022
Figure 28. Global Giant Cell Arteritis Therapeutic Consumption Value Share by Type (2018-2023)
Figure 29. Global Giant Cell Arteritis Therapeutic Market Share Forecast by Type (2024-2029)
Figure 30. Global Giant Cell Arteritis Therapeutic Consumption Value Share by Application (2018-2023)
Figure 31. Global Giant Cell Arteritis Therapeutic Market Share Forecast by Application (2024-2029)
Figure 32. North America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 42. France Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value Market Share by Region (2018-2029)
Figure 49. China Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 52. India Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 66. Giant Cell Arteritis Therapeutic Market Drivers
Figure 67. Giant Cell Arteritis Therapeutic Market Restraints
Figure 68. Giant Cell Arteritis Therapeutic Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Giant Cell Arteritis Therapeutic in 2022
Figure 71. Manufacturing Process Analysis of Giant Cell Arteritis Therapeutic
Figure 72. Giant Cell Arteritis Therapeutic Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Figure 1. Giant Cell Arteritis Therapeutic Picture
Figure 2. Global Giant Cell Arteritis Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type in 2022
Figure 4. Prednisone
Figure 5. Methotrexate
Figure 6. Tocilizumab
Figure 7. Aspirin
Figure 8. Global Giant Cell Arteritis Therapeutic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application in 2022
Figure 10. Corticosteroids Picture
Figure 11. Immunosuppressive Agents Picture
Figure 12. Anticoagulants Picture
Figure 13. Others Picture
Figure 14. Global Giant Cell Arteritis Therapeutic Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Giant Cell Arteritis Therapeutic Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Giant Cell Arteritis Therapeutic Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Giant Cell Arteritis Therapeutic Consumption Value Market Share by Region in 2022
Figure 19. North America Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Giant Cell Arteritis Therapeutic Revenue Share by Players in 2022
Figure 25. Giant Cell Arteritis Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Giant Cell Arteritis Therapeutic Market Share in 2022
Figure 27. Global Top 6 Players Giant Cell Arteritis Therapeutic Market Share in 2022
Figure 28. Global Giant Cell Arteritis Therapeutic Consumption Value Share by Type (2018-2023)
Figure 29. Global Giant Cell Arteritis Therapeutic Market Share Forecast by Type (2024-2029)
Figure 30. Global Giant Cell Arteritis Therapeutic Consumption Value Share by Application (2018-2023)
Figure 31. Global Giant Cell Arteritis Therapeutic Market Share Forecast by Application (2024-2029)
Figure 32. North America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 42. France Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Giant Cell Arteritis Therapeutic Consumption Value Market Share by Region (2018-2029)
Figure 49. China Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 52. India Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Giant Cell Arteritis Therapeutic Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Giant Cell Arteritis Therapeutic Consumption Value (2018-2029) & (USD Million)
Figure 66. Giant Cell Arteritis Therapeutic Market Drivers
Figure 67. Giant Cell Arteritis Therapeutic Market Restraints
Figure 68. Giant Cell Arteritis Therapeutic Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Giant Cell Arteritis Therapeutic in 2022
Figure 71. Manufacturing Process Analysis of Giant Cell Arteritis Therapeutic
Figure 72. Giant Cell Arteritis Therapeutic Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
